ALSO NOTED: Roche accepts judge's deal on Mircera; Pharma stocks weathered yesterday's craziness;

> Breaking news: Roche said it agreed to a judge's conditions for its launch of the anemia drug Mircera, which Amgen had attacked for patent infringement; the conditions include a higher royalty for Amgen. Report

> How did drug stocks fare in yesterday's crazy market? Erratically, just like most others, but the pharma index ended the day up by 1.25 percent. Report

> EastPharma is buying marketing rights to eight Roche products registered in Turkey, including cardio and central nervous system meds. Report

> Denmark's Lifecycle Pharma is commencing a rights offering of 24 million new shares, with preemptive rights for current shareholders, in hopes of raising $86.5 million. Report

> Glenmark Pharmaceuticals launched five dermatology products designed to treat eczema and psoriasis. Report

> A new computer model developed at the University of California at Los Angeles can identify effective drug combinations and their recommended doses. Report

And Finally... What do you get when you mix 20 drug developers active in the diabetes field with a room full of geneticists? Hopefully, a new generation of therapies that pinpoint subsets of the disease. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.